^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Angiogenesis inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
Published date:
11/14/2022
Excerpt:
KRAS mutant NSCLC patients received chemotherapy or immunotherapy as first-line treatment from September 2014 to March 2022 were enrolled….In terms of different chemotherapy regimen, platinum-paclitaxel combined with antiangiogenic therapy achieved the highest ORR and DCR (P < 0.05), while the platinum-pemetrexed combined with antiangiogenic therapy had the longest PFS and OS (P < 0.001).
Secondary therapy:
paclitaxel; pemetrexed
DOI:
https://doi.org/10.1186/s12885-022-10236-9
